Patents by Inventor Hicham Alaoui
Hicham Alaoui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970722Abstract: The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.Type: GrantFiled: December 18, 2020Date of Patent: April 30, 2024Assignee: Codexis, Inc.Inventors: William Casey Hallows, Rachel Cathleen Botham, Yu Zhu, Chinping Chng, Nikki Dellas, Gjalt W. Huisman, Moulay Hicham Alaoui Ismaili, David William Homan, Adam P. Silverman, Jonathan Vroom, Jessica P. Lao
-
Patent number: 11959108Abstract: The present invention provides engineered protease polypeptides and compositions thereof. The engineered protease polypeptides have been optimized to provide improved activity, improved thermostability, protease stability, autolytic stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered protease polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered protease polypeptides, as well as methods for making the engineered polynucleotides and protease polypeptides.Type: GrantFiled: August 27, 2021Date of Patent: April 16, 2024Assignees: Codexis, Inc., Societe des Produits Nestle S.A.Inventors: Chinping Chng, Nikki Dellas, Ravi David Garcia, Moulay Hicham Alaoui Ismaili, Kristen Jean Vallieu, Kerryn McCluskie
-
Publication number: 20230416825Abstract: Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Sydrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.Type: ApplicationFiled: March 29, 2023Publication date: December 28, 2023Applicant: Genentech, Inc.Inventors: Amy Dressen, David B. Iaea, Moulay Hicham Alaoui Ismaili, Janet K. Jackman, Robert A. Lazarus, Kelly Michele Loyet, Henry R. Maun, Brian Louis Yaspan, Tangsheng Yi, Joseph R. Arron, Hilda Y Hernandez-Barry
-
Publication number: 20220356458Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: ApplicationFiled: July 22, 2022Publication date: November 10, 2022Inventors: William Casey Hallows, Kristen Jean Vallieu, Nikki Dellas, Yu Zhu, Judy Victoria Antonio Viduya, Chinping Chng, Antoinette Sero, Gjalt W. Huisman, Rachel Cathleen Botham, Moulay Hicham Alaoui Ismaili
-
Patent number: 11427813Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: GrantFiled: December 19, 2019Date of Patent: August 30, 2022Assignee: Codexis, Inc.Inventors: William Casey Hallows, Kristen Jean Vallieu, Nikki Dellas, Yu Zhu, Judy Victoria Antonio Viduya, Chinping Chng, Antoinette Sero, Gjalt W. Huisman, Rachel Cathleen Botham, Moulay Hicham Alaoui Ismaili
-
Publication number: 20220090039Abstract: The present invention provides engineered protease polypeptides and compositions thereof. The engineered protease polypeptides have been optimized to provide improved activity, improved thermostability, protease stability, autolytic stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered protease polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered protease polypeptides, as well as methods for making the engineered polynucleotides and protease polypeptides.Type: ApplicationFiled: August 27, 2021Publication date: March 24, 2022Inventors: Chinping Chng, Nikki Dellas, Ravi David Garcia, Moulay Hicham Alaoui Ismaili, Kristen Jean Vallieu, Kerryn McCluskie
-
Publication number: 20210301032Abstract: The invention provides anti-KLK5 antibodies and methods of using the same.Type: ApplicationFiled: November 17, 2020Publication date: September 30, 2021Applicant: Genentech, Inc.Inventors: Cecilia P.C. Chiu, Hilda Y. Hernandez-Barry, David B. Iaea, Moulay Hicham Alaoui-Ismaili, James T. Koerber, Wei Yu Lin, Kelly Loyet, Yonglian Sun, Benjamin T. Walters, Jawahar Sudhamsu
-
Publication number: 20210269787Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: ApplicationFiled: February 26, 2021Publication date: September 2, 2021Inventors: William Casey Hallows, Nikki Dellas, Yu Zhu, Judy Victoria Antonio Viduya, Chinping Chng, Antoinette Sero, Rachel Cathleen Botham, David William Homan, Moulay Hicham Alaoui Ismaili, Jonathan Vroom, Adam P. Silverman, Kristen Jean Vallieu, Charu Shukla Reddy, Kerryn McCluskie
-
Publication number: 20210246176Abstract: The present invention provides mucin-binding fusion proteins suitable for extending the residence time of oral therapeutics in the intestinal tract.Type: ApplicationFiled: January 22, 2021Publication date: August 12, 2021Inventors: Marcus Rohovie, Nikki Dellas, Moulay Hicham Alaoui Ismaili
-
Publication number: 20210189365Abstract: The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.Type: ApplicationFiled: December 18, 2020Publication date: June 24, 2021Inventors: William Casey Hallows, Rachel Cathleen Botham, Yu Zhu, Chinping Chng, Nikki Dellas, Gjalt W. Huisman, Moulay Hicham Alaoui Ismaili, David William Homan, Adam P. Silverman, Jonathan Vroom, Jessica P. Lao
-
Publication number: 20200040103Abstract: The invention provides anti-KLK5 antibodies and methods of using the same.Type: ApplicationFiled: March 13, 2019Publication date: February 6, 2020Applicant: Genentech, Inc.Inventors: Cecilia P. C. Chiu, Hilda Y. Hernandez-Barry, David B. Iaea, Moulay Hicham Alaoui-Ismaili, James T. Koerber, Wei Yu Lin, Kelly Loyet, Yonglian Sun, Benjamin T. Walters, Jawahar Sudhamsu
-
Publication number: 20190078160Abstract: Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Syndrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.Type: ApplicationFiled: April 20, 2018Publication date: March 14, 2019Applicant: Genentech, Inc.Inventors: Amy Dressen, David B. Iaea, Moulay Hicham Alaoui Ismaili, Janet K. Jackman, Robert A. Lazarus, Kelly Loyet, Henry R. Maun, Brian L. Yaspan, Tangsheng Yi, Joseph R. Arron, Hilda Y. Hernandez-Barry
-
Publication number: 20140162273Abstract: The present invention relates to methods of detecting neutralizing antibodies for bone morphogenetic proteins (BMP). More particularly, it relates to a highly specific, robust, rapid and accurate cell-based assay for detecting the presence of anti-BMP neutralizing antibodies.Type: ApplicationFiled: August 23, 2013Publication date: June 12, 2014Applicant: Stryker CorporationInventors: Hicham Alaoui, Karen Lavery
-
Publication number: 20130184208Abstract: The present invention provides modified, highly potent bone morphogenetic proteins. In particular, the present invention relates to the observation that BMP-6 and BMP-9 are less susceptible to inhibition by Noggin that are other members of the BMP subfamily of proteins. The present invention features chimeric bone morphogenetic proteins in which the middle portion of BMP-6 or BMP-9 replaces the middle portion of another BMP subfamily protein to cause resistance to inhibition by Noggin or other Noggin-like antagonists. Other embodiments of modified BMPs, compositions and methods of use are also included.Type: ApplicationFiled: November 30, 2012Publication date: July 18, 2013Inventors: Moulay Hicham Alaoui-Ismaili, Kening Song
-
Publication number: 20120148539Abstract: Disclosed herein are methods and compositions for promoting endochondral bone formation. The invention includes methods of promoting endochondral bone formation by down-regulating the expression of the DIO2 gene or the activity of the deiodinase protein. The invention also includes methods of up-regulating the activity of the FGFR3, ADAMTS9, HEY1, HAS3, and/or MFI2 genes and/or the activity of the expression products of those genes to promote endochondral bone formation. The invention also includes compositions of BMP-7 and agonists of FGFR3, ADAMTS9, HEY1, HAS3, and/or MFI2 proteins. Compositions can further include mesenchymal stem cells.Type: ApplicationFiled: February 19, 2010Publication date: June 14, 2012Inventor: Moulay Hicham Alaoui-Ismaili
-
Publication number: 20110039773Abstract: The present invention provides modified, highly potent bone morphogenetic proteins. In particular, the present invention relates to the observation that BMP-6 and BMP-9 are less susceptible to inhibition by Noggin that are other members of the BMP subfamily of proteins. The present invention features chimeric bone morphogenetic proteins in which the middle portion of BMP-6 or BMP-9 replaces the middle portion of another BMP subfamily protein to cause resistance to inhibition by Noggin or other Noggin-like antagonists. Other embodiments of modified BMPs, compositions and methods of use are also included.Type: ApplicationFiled: December 19, 2008Publication date: February 17, 2011Applicant: Stryker BiotechInventors: Moulay Hicham Alaoui-Ismaili, Kening Song
-
Publication number: 20100209926Abstract: The present invention relates to methods of detecting neutralizing antibodies for bone morphogenetic proteins (BMP). More particularly, it relates to a highly specific, robust, rapid and accurate cell-based assay for detecting the presence of anti-BMP neutralizing antibodies.Type: ApplicationFiled: September 26, 2008Publication date: August 19, 2010Applicant: Stryker CorporationInventors: Hicham Alaoui, Karen Lavery